Skip to main content

Research Repository

Advanced Search

All Outputs (14)

Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production (2020)
Journal Article
Atkinson, S. K., Morice, A. H., & Sadofsky, L. R. (2020). Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production. ERJ Open Research, 6(4), Article 00159-2020. https://doi.org/10.1183/23120541.00159-2020

Human rhinovirus (RV) is the most common cause of upper respiratory tract infection (URTI) and chronic airway disease exacerbation. Cough is present in 50–80% of URTI cases, accompanied by heightened airway hypersensitivity, yet no effective treatmen... Read More about Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production.

Azithromycin for sarcoidosis cough: an open label exploratory clinical trial (2020)
Journal Article
Fraser, S. D., Thackray-Nocera, S., Shepherd, M., Flockton, R., Wright, C., Sheedy, W., Brindle, K., Morice, A. H., Kaye, P. M., Crooks, M. G., & Hart, S. P. (2020). Azithromycin for sarcoidosis cough: an open label exploratory clinical trial. ERJ Open Research, 6(4), Article 00534. https://doi.org/10.1183/23120541.00534-2020

Background: Chronic cough is a distressing symptom for many people with pulmonary sarcoidosis. Continuous treatment with a macrolide antibiotic may improve cough. We aimed to assess the potential efficacy of azithromycin in patients with sarcoidosis... Read More about Azithromycin for sarcoidosis cough: an open label exploratory clinical trial.

An audit of COPD: Diagnosis and management in general practice (2020)
Journal Article
Hamad, G., Rigby, A., & Morice, A. H. (2020). An audit of COPD: Diagnosis and management in general practice. ERJ Open Research, 6(4), Article 00330-2020. https://doi.org/10.1183/23120541.00330-2020

Introduction: COPD is a spectrum of disorders primarily caused by smoking and characterised by progressive, not fully reversible airflow obstruction with a forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.7. Methods: From N...

Design and rationale of two phase 3 randomised controlled trials (Cough-1 and cough-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough (2020)
Journal Article
Muccino, D. R., Morice, A. H., Birring, S. S., Dicpinigaitis, P. V., Pavord, I. D., Assaid, C., …Smith, J. A. (2020). Design and rationale of two phase 3 randomised controlled trials (Cough-1 and cough-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough. ERJ Open Research, 6(4), Article 00284-2020. https://doi.org/10.1183/23120541.00284-2020

Background: We present study designs, dose selection and preliminary patient characteristics from two phase 3 clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough (RCC) or unexplained chronic cough (UCC). Methods: CO... Read More about Design and rationale of two phase 3 randomised controlled trials (Cough-1 and cough-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.

Alert system design based on experimental findings from long-term unobtrusive monitoring in COPD (2020)
Journal Article
den Brinker, A. C., van Dinther, R., Crooks, M. G., Thackray-Nocera, S., & Morice, A. H. (2021). Alert system design based on experimental findings from long-term unobtrusive monitoring in COPD. Biomedical Signal Processing and Control, 63, Article 102205. https://doi.org/10.1016/j.bspc.2020.102205

An observational study using a cough count monitor was executed in the home of 30 patients with Chronic Obstructive Pulmonary Disease (COPD). The monitoring system was unobtrusive, allowing long-term monitoring. This paper illustrates the cough count... Read More about Alert system design based on experimental findings from long-term unobtrusive monitoring in COPD.

Objective Assessment of Cough: An Early Marker of Response to Biological Therapies in Asthma? (2020)
Journal Article
Faruqi, S., Sykes, D. L., Crooks, M. G., Brindle, K., Thompson, J., & Morice, A. H. (2020). Objective Assessment of Cough: An Early Marker of Response to Biological Therapies in Asthma?. Lung, 198(5), 767-770. https://doi.org/10.1007/s00408-020-00391-w

© 2020, Springer Science+Business Media, LLC, part of Springer Nature. Cough is an important symptom of asthma. The objective assessment of chronic cough has been enhanced by the development of ambulatory cough monitoring systems. Mepolizumab has bee... Read More about Objective Assessment of Cough: An Early Marker of Response to Biological Therapies in Asthma?.

Impact of chronic cough on health-related quality of life in the Korean adult general population: The Korean National Health and Nutrition Examination Survey 2010–2016 (2020)
Journal Article
Won, H.-K., Lee, J.-H., An, J., Sohn, K.-H., Kang, M.-G., Kang, S.-Y., Morice, A. H., Cho, S.-H., & Song, W.-J. (2020). Impact of chronic cough on health-related quality of life in the Korean adult general population: The Korean National Health and Nutrition Examination Survey 2010–2016. Allergy Asthma and Immunology Research, 12(6), 964-979. https://doi.org/10.4168/aair.2020.12.6.964

Purpose: Chronic cough is a prevalent condition in the community and may pose considerable impairment to quality of life (QoL). However, its disease burden remains largely undefined in the general population. The present study investigated the relati... Read More about Impact of chronic cough on health-related quality of life in the Korean adult general population: The Korean National Health and Nutrition Examination Survey 2010–2016.

Cough persistence in adults with chronic cough: a 4-year retrospective cohort study (2020)
Journal Article
Kang, S. Y., Song, W. J., Won, H. K., Chung, S. J., Kim, J. Y., Park, H. W., Morice, A. H., & Cho, S.-H. (2020). Cough persistence in adults with chronic cough: a 4-year retrospective cohort study. Allergology International, 69(4), 588-593. https://doi.org/10.1016/j.alit.2020.03.012

Background
There is very limited evidence regarding long-term prognosis of chronic cough. We examined longitudinal outcomes among patients with chronic cough, and explored predictors of cough persistence.
Methods
A retrospective cohort was constru... Read More about Cough persistence in adults with chronic cough: a 4-year retrospective cohort study.

Drug-induced cough (2020)
Journal Article
Shim, J. S., Song, W. J., & Morice, A. H. (2020). Drug-induced cough. Physiological Research, 69(S1), S81-S92. https://doi.org/10.33549/physiolres.934406

© 2020, Czech Academy of Sciences. Since the recognition of angiotensin-converting enzyme inhibitors (ACEIs)-induced cough, drug has been considered as a potential cause of chronic cough. This review presents recent knowledge on drug-induced coughs i... Read More about Drug-induced cough.

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial (2020)
Journal Article
Smith, J. A., Kitt, M. M., Morice, A., Birring, S. S., McGarvey, L. P., Sher, M. R., Li, Y. P., Wu, W. C., Xu, Z. J., Muccino, D. R., Ford, A. P., Hull, J., Carr, W. W., Goldsobel, A. B., Gross, G. N., Holcomb, J. R., Hussain, I., Spangenthal, S., Storms, W., Elkayam, D., …Iyer, V. (2020). Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. The lancet. Respiratory medicine, 8(8), 775-785. https://doi.org/10.1016/S2213-2600%2819%2930471-0

Background: Gefapixant is a P2X3 receptor antagonist that has shown promise for the treatment of refractory and unexplained chronic cough. The aim of this study was to evaluate the efficacy of gefapixant compared with placebo after 12 weeks of treatm... Read More about Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.